1. Home
  2. BCRX
  3. BCRX News

Latest BioCryst Pharmaceuticals Inc. (BCRX) News on June 2, 2025

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
BCRX

GlobeNewswire

3 days ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
BCRX

Zacks

5 days ago

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

BioCryst to Present at Upcoming Investor Conferences
BCRX

GlobeNewswire

6 days ago

BioCryst to Present at Upcoming Investor Conferences

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade
BCRX

Zacks

7 days ago

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade

BCRX

MT Newswires

17 days ago

Sector Update: Health Care Stocks Flat to Higher Premarket Friday

BCRX

MT Newswires

17 days ago

BioCryst Says Orladeyo Prompted 'Significant' Drop Hereditary Angioedema Attacks in Study

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)
BCRX

GlobeNewswire

17 days ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

FDA awards BioCryst’s Orladeyo NDA for paediatric HAE
BCRX

Pharmaceutical Technology

18 days ago

FDA awards BioCryst’s Orladeyo NDA for paediatric HAE

BCRX

MT Newswires

19 days ago

BioCryst Pharmaceuticals Says FDA Grants Priority Review for Orladeyo in Children

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years
BCRX

GlobeNewswire

19 days ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

Best Momentum Stocks to Buy for May 9th
BCRX

Zacks

24 days ago

Best Momentum Stocks to Buy for May 9th

Why BioCryst (BCRX) Might be Well Poised for a Surge
BCRX

Zacks

25 days ago

Why BioCryst (BCRX) Might be Well Poised for a Surge

What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?
BCRX

Zacks

25 days ago

What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?

Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?
BCRX

Zacks

25 days ago

Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results
BCRX

Simply Wall St.

25 days ago

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

BCRX

MT Newswires

a month ago

RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating

Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday
BCRX

Insider Monkey

a month ago

Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday

BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ...
BCRX

GuruFocus.com

a month ago

BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ...

BCRX

Thomson Reuters StreetEvents

a month ago

Q1 2025 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1
BCRX

Zacks

a month ago

BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1

BCRX

MT Newswires

a month ago

BioCryst Pharmaceuticals Reports Breakeven in Q1, Higher Revenue; Shares up Pre-Bell

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
BCRX

GlobeNewswire

a month ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

High Growth Tech Stocks To Watch In The US May 2025
BCRX

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In The US May 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

a month ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Appoints Steve Frank to Board of Directors
BCRX

GlobeNewswire

a month ago

BioCryst Appoints Steve Frank to Board of Directors

Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BCRX

Zacks

a month ago

Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst to Present at Upcoming Investor Conferences
BCRX

GlobeNewswire

a month ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BCRX

Zacks

a month ago

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst to Report First Quarter 2025 Financial Results on May 5
BCRX

GlobeNewswire

a month ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry
BCRX

Zacks

2 months ago

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

BCRX

MT Newswires

2 months ago

BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

2 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at Upcoming Investor Conference
BCRX

GlobeNewswire

2 months ago

BioCryst to Present at Upcoming Investor Conference

High Growth Tech Stocks In The US Market With Promising Potential
BCRX

Simply Wall St.

2 months ago

High Growth Tech Stocks In The US Market With Promising Potential

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%
BCRX

Simply Wall St.

2 months ago

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

3 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRX

MT Newswires

3 months ago

BioCryst Pharmaceuticals CFO Anthony Doyle to Step Down

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?
BCRX

Insider Monkey

3 months ago

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
BCRX

Zacks

3 months ago

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
BCRX

Zacks

3 months ago

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
BCRX

Zacks

3 months ago

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results
BCRX

Simply Wall St.

3 months ago

Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results

Company News for Feb 25, 2025
BCRX

Zacks

3 months ago

Company News for Feb 25, 2025

BCRX

MT Newswires

3 months ago

RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating

BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations
BCRX

Simply Wall St.

3 months ago

BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

BCRX

Thomson Reuters StreetEvents

3 months ago

Q4 2024 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...
BCRX

GuruFocus.com

3 months ago

BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
BCRX

Motley Fool

3 months ago

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript
BCRX

Motley Fool

3 months ago

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
BCRX

Zacks

3 months ago

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

BCRX

MT Newswires

3 months ago

BioCryst Says Interim Data Show Orladeyo Reduced Attack Rates in Pediatric Patients With Hereditary Angioedema

BCRX

MT Newswires

3 months ago

BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows, Revenue Rises

BCRX

Associated Press Finance

3 months ago

BioCryst: Q4 Earnings Snapshot

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
BCRX

GlobeNewswire

3 months ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
BCRX

GlobeNewswire

3 months ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

BioCryst to Present at Upcoming Investor Conferences
BCRX

GlobeNewswire

3 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BCRX

Zacks

4 months ago

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BCRX

MT Newswires

4 months ago

BioCryst Says Orladeyo Recommended for Hereditary Angioedema Prevention in Portugal

BioCryst Launches ORLADEYO® (berotralstat) in Portugal
BCRX

GlobeNewswire

4 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Exploring Three High Growth Tech Stocks In The United States
BCRX

Simply Wall St.

4 months ago

Exploring Three High Growth Tech Stocks In The United States

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
BCRX

GlobeNewswire

4 months ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
BCRX

GlobeNewswire

4 months ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

4 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock
BCRX

Simply Wall St.

4 months ago

Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock

BioCryst price target raised to $12 from $10 at Evercore ISI
BCRX

TipRanks

5 months ago

BioCryst price target raised to $12 from $10 at Evercore ISI

Exploring High Growth Tech Stocks In January 2025
BCRX

Simply Wall St.

5 months ago

Exploring High Growth Tech Stocks In January 2025

BCRX

MT Newswires

5 months ago

BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
BCRX

GlobeNewswire

5 months ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
BCRX

GlobeNewswire

5 months ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

5 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%
BCRX

Simply Wall St.

5 months ago

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

High Growth Tech Stocks To Watch In December 2024
BCRX

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In December 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

6 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future
BCRX

Simply Wall St.

6 months ago

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future

BCRX

MT Newswires

6 months ago

BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator

BioCryst Launches ORLADEYO® (berotralstat) in Ireland
BCRX

GlobeNewswire

6 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

BioCryst to Present at Upcoming Investor Conferences
BCRX

GlobeNewswire

7 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Announces Strong Q3 2024 Revenue Growth
BCRX

TipRanks

7 months ago

BioCryst Announces Strong Q3 2024 Revenue Growth

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

7 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
BCRX

Simply Wall St.

7 months ago

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

BCRX

Thomson Reuters StreetEvents

7 months ago

Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...
BCRX

GuruFocus.com

7 months ago

BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript
BCRX

Motley Fool

7 months ago

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
BCRX

Zacks

7 months ago

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

BCRX

MT Newswires

7 months ago

BioCryst Pharmaceuticals Q3 Loss Narrows, Revenue Rises; 2024 Sales Guidance Issued

BCRX

Associated Press Finance

7 months ago

BioCryst: Q3 Earnings Snapshot

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
BCRX

GlobeNewswire

7 months ago

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)
BCRX

GlobeNewswire

7 months ago

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%
BCRX

Zacks

7 months ago

How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%

High Growth Tech Stocks To Watch In October 2024
BCRX

Simply Wall St.

7 months ago

High Growth Tech Stocks To Watch In October 2024

BioCryst to Report Third Quarter 2024 Financial Results on November 4
BCRX

GlobeNewswire

7 months ago

BioCryst to Report Third Quarter 2024 Financial Results on November 4

State Street Corp's Strategic Reduction in BioCryst Pharmaceuticals Holdings
BCRX

GuruFocus.com

8 months ago

State Street Corp's Strategic Reduction in BioCryst Pharmaceuticals Holdings

BCRX

MT Newswires

8 months ago

BioCryst Pharmaceuticals' Study of Orladeyo Finds Hospitalization Reduction for Hereditary Angioedema Patients

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
BCRX

GlobeNewswire

8 months ago

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?
BCRX

Insider Monkey

8 months ago

Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
BCRX

GlobeNewswire

8 months ago

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2
BCRX

Insider Monkey

8 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2

BioCryst (BCRX) Upgraded to Buy: Here's Why
BCRX

Zacks

8 months ago

BioCryst (BCRX) Upgraded to Buy: Here's Why

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

8 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
BCRX

Zacks

8 months ago

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?

Share on Social Networks: